FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB APPROVAL											
OMB Number:	OMB Number: 3235-0287										
Estimated average burden											
hours per response:	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Lippoldt Darin				ssuer Name and Ti EUROCRINE BIX]		g Symbol ENCES INC [(Check	tionship of Reporti all applicable) Director Officer (give title	10% 0			
(Last) 12780 EL CAM	(First) IINO REAL	(Middle	, J.,	Date of Earliest Tra /18/2022	nsaction (Mon	th/Day/Year)		below)	below gal Officer			
(Street) SAN DIEGO	CA	92130		f Amendment, Date	e of Original Fi	led (Month/Day/Year)	6. Indiv Line) X	vidual or Joint/Grou Form filed by On				
(City)	(State)	(Zip)						Form filed by Mo Person	re than One Re	porting		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/)				2A. Deemed Execution Date,	3. Transaction	4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4		5. Amount of Securities Beneficially	6. Ownership Form: Direct	7. Nature of Indirect Beneficial		

	(Month/Day/Year)	if any (Month/Day/Year)	Code (8)	Instr.			Beneficially Owned Following Reported	(D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(11150. 4)
Common Stock	03/18/2022		S ⁽¹⁾		300	D	\$ <mark>9</mark> 5	37,851	D	
Common Stock	03/22/2022		S ⁽¹⁾		8,455	D	\$95.051 ⁽²⁾	29,396 ⁽³⁾	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(0/1	,	,		,	• •				,			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions consistent with Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. 2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$95.00 to \$95.17. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. 3. Includes an aggregate of 39 shares purchased on February 28, 2022 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.

Remarks:



03/22/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.